Research programme: nuclear hormone receptor modulators - Galapagos/Eli Lilly

Drug Profile

Research programme: nuclear hormone receptor modulators - Galapagos/Eli Lilly

Alternative Names: Nuclear hormone receptor modulators research programme - BioFocus/Eli Lilly

Latest Information Update: 03 Feb 2009

Price : $50

At a glance

  • Originator Eli Lilly; Galapagos NV
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 03 Feb 2009 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 14 Jan 2008 Biofocus DPI and Eli Lilly have extended their drug discovery agreement until the end of 2008
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top